Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

113.13 +4.90 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
65 66 Next >
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
Shares crumbled after Moderna's flu shot outperformed in just one flu strain. 
Via Investor's Business Daily
Why Is Moderna (MRNA) Stock Down 5% Today?
If Moderna's new formulation works the latest failure will be a short-term hiccup. But MRNA stock also faces legal and PR challenges. 
Via InvestorPlace
Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents
Via Benzinga
Is Novavax Stock a Buy With the New Normal for COVID?
The landscape has shifted dramatically in the COVID-19 vaccine market. 
Via The Motley Fool
The 3 Most Undervalued Growth Stocks for Your February Buy List
These undervalued growth stocks have the value and projected growth that investors seek when researching their next investment decisions. 
Via InvestorPlace
Better Buy: Novavax or BioNTech Stock?
The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot. 
Via The Motley Fool
Analyst Ratings for BioNTech
Via Benzinga
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. 
Via InvestorPlace
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
From BioNTech SE
Via GlobeNewswire
Novavax Shares Jumped in January While Others Slipped
Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line. 
Via MarketBeat
Exposures COVID-19 Product Safety
Why BioNTech And Moderna Shares Are Falling After Pfizer News
BioNTech SE - ADR (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) shares are trading lower Tuesday morning in sympathy with Pfizer Inc. (NYSE: 
Via Benzinga
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths. 
Via Benzinga
Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip
The FDA's experts voted in favor of annual boosters on Thursday. 
Via Investor's Business Daily
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
Thursday Predictions: 3 Hot Stocks for Tomorrow
Airline stocks, credit card stocks, and vaccine stocks are our focus when it comes to the hot stocks for tomorrow. Here's why. 
Via InvestorPlace
COVID-19 Vaccine Strategy Might Follow The Influenza Shot Way, FDA To Decide Today
The FDA is considering a significant shift in the U.S.'s COVID-19 vaccine strategy to simplify vaccination against COVID-19. 
Via Benzinga
Google Layoffs 12K Employees, Netflix's Q4 Earnings And CEO Steps Down, FDA Rejects Eli Lilly's Alzheimer's Candidate: Top Stories Friday, Jan. 20
Here's a round-up of stories from around the globe and from various media outlets. Benzinga 
Via Benzinga
Israel Says No Stroke Risk Associated With Pfizer/BioNTech Updated COVID-19 Shots
Israel health ministry official said Isreal had not identified any evidence linking strokes to an updated coronavirus vaccine by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX). 
Via Benzinga
Pfizer (PFE) Stock Falls on Analyst Downgrade
Although Pfizer led the charge in forwarding Covid-19 solutions, possibly waning relevancy poses serious concerns for PFE stock. 
Via InvestorPlace
Pfizer Stock Dives As Analyst Calls For 'Covid Reset' And Downgrades Shares
Shares have skidded almost 10% in the first two weeks of 2023. 
Via Investor's Business Daily
US Health Agencies Investigate Preliminary COVID-19 Vaccine Safety Signal In Older People
The U.S. 
Via Benzinga
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand. 
Via Benzinga
Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing”
Small-cap speculative biotech stocks regain interest with volatility. 
Via Talk Markets
BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British Startup
Via Benzinga
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
From BioNTech SE
Via GlobeNewswire
Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly
Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) reduced hospitalizations among older patients. 
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
2 Top Biotech Stocks to Buy Right Now
These two pharmaceutical companies pay market-beating dividends to shareholders. 
Via The Motley Fool
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
From BioNTech SE
Via GlobeNewswire
Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.